Tag: Galaxy Therapeutics
Galaxy completes enrolment in pivotal trial evaluating Seal intrasaccular device
Galaxy Therapeutics has announced it has successfully completed enrolment in SEAL IT, the company’s US investigational device exemption (IDE) pivotal trial evaluating the Seal...
Galaxy Therapeutics completes enrolment of primary cohort in pivotal SEAL IT...
Galaxy Therapeutics has today announced completed enrolment of the primary cohort of patients in its SEAL IT investigational device exemption (IDE) trial.
The trial's primary...
“The third way” in intrasaccular aneurysm treatment demonstrates positive one-year outcomes
A device labelled “the third way” to potentially treat intracranial aneurysms via an intrasaccular approach has demonstrated positive effectiveness and safety results at one...
